Systemic Therapy of HER2-positive Breast Cancer
|
|
- Moses Warren
- 6 years ago
- Views:
Transcription
1 Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017
2 Relative Risk HER2-positive Breast Cancer 1 0,9 0,8 0,7 0,6 0,5 0,4 0,3 0,2 0,1 0 Adjuvant trastuzumab trials: Relative risk reduction of death 1 Risk od death 33-59% 0,66 0,67 0,67 0,41 0,59 0,66 HER2-directed therapy in ABC: Survival rates Courtesy of M. Piccart Mendes D, et al. Breast Cancer Res HER2-directed therapy one of the largest achievements! HER2 is a molecular driver of approx. 20% of BC. EBC: Death reduction risk by approx. 30%. MBC: Doubling of overall survival time.
3 Adjuvant HER2-directed Therapy
4 HERA: 1 year or 2 years of Trastuzumab after Cht vs. Observation HR 0.75; Δ 7.0% HR 0.74; Δ 6.0% Piccart M, ASCO 2015, Untch M, et al. Ann Oncol Goldhirsch A, et al. Lancet 2013.
5 NCCTG N9831: 1 year Trastuzumab Concurrent or Sequential with Cht vs. Cht alone Perez, et al. Cancer Res 2009.
6 HR + HR - Trastuzumab in T 2cm N0: Meta-Analysis O Sullivan C, et al. J Clin Oncol Only 75 pts 1 cm ( T1a/b N0).
7 Escalation and De-escalation of Adjuvant Anti- HER2 Therapy Adjuvant treatment if no pcr KATHERINE: T-DM1 (on-going) Non-anthracycline-based CT BCIRG 006: TCH regimen (positive) APT: weekly P + H (positive) Escalating targeted agents BETH: H + Bevacizumab (negative) ExteNET: H -> neratinib (positive) ALTTO: H -> L or H+L (negative) APHINITY: H + pertuzumab (positive) KAITLIN: T-DM1 + pertuzumab (on-going) ANTHRACYCLINE AND TAXANE BASED CHEMOTHERAPY WITH TRASTUZUMAB FOR ONE YEAR CT-free regimen ATEMPT: T-DM1 (on-going) Adoped from Lambertini M, et al. Expert Rev Cancer Ther Prolonging duration of adjuvant H HERA: H for 2 years (negative) Reducing duration of adjuvant H FinHer: H for 9 weeks (negative) PHARE: H for 6 months (negative) HORG trial: H for 6 months (negative) SHORT-HER: H for 3 months (negative) PERSEPHONE: H for 6 months (on-going) SOLD: H for 9 weeks (on-going)
8 ExteNET: 1 year Neratinib after 1 year of Trastuzumab vs. 1 year Trastuzumab Substantial toxicity (40% G3/4 diarrhea). Chan A, et al. Lancet Oncology Positive DFS data persist with longer FU (3-year DFS, SABCS 2015). OS data are still pending!
9 ALTTO: 1 year Trastuzumab plus Lapatinib (concurrent or Sequential) vs. Trastuzumab * Bracketed data in all KM curves represent results of the Primary Analysis ASCO 2014 Δ 3.0% Alvaro Moreno-Aspitia, et at. ASCO 2017, Abstract 502.
10 ALTTO: 1 year Trastuzumab plus Lapatinib (concurrent ALTTO Updated or Sequential) Results vs. Trastuzumab Alvaro Moreno-Aspitia, et at. ASCO 2017, Abstract 502. Δ 2.0% Δ 4.0%
11 APHINITY: 1 year Trastuzumab plus Pertuzumab vs. 1 year Trastuzumab plus von Minckwitz G, et al. N Engl J Med Expected: 89.2% 4yr idfs absolute benefit = 1.7% Number needed to treat: 112
12 APHINITY: 1 year Trastuzumab plus Pertuzumab vs. 1 year Trastuzumab plus The effect of pertuzumab on idfs was homogenous across all subgroups. No significant interaction for any subgroup, including N status and HR status. von Minckwitz G, et al. N Engl J Med Δ 3.2% Δ 2.3%
13 Escalating HER2-directed Adjuvant Therapy Trial HERA Cameron D, et al. Lancet ExteNET Chan A, et al. Lancet Oncol ALTTO Piccart-Gebhart M, et al. J Clin Oncol Moreno-Asptia A et al., ASCO 2017 Abstr 502. APHINITY von Minckwitz G et al., NEJM 2017 Study Design Phase 3 Phase 3 Phase 3 Phase DFS No. of Treatment Arm Absolute values Patients HR (95% CI; p) Longer duration of HER2-directed therapy OS Absolute values HR (95% CI; p) 1,552 CT + trastuzumab 1 yr 10-year DFS: 73.9% 12-year OS: 86.1% 1,553 CT + trastuzumab 2 yrs 10-year DFS: 73.1% 1.02 ( ; 0.796) 1,420 CT + trastuzumab 1 yr + 2-years IDFS: 91.6% placebo for another year 1,420 CT + trastuzumab 1 yr + 2-years IDFS: 93.9% neratinib for another 1 yr 0.67 ( ; ) Dual HER2-directed therapy 12-year OS: 83.6% 1.01 ( ; 0.916) NR 2,097 CT + trastuzumab 1 year 6-year DFS: 82.0% 6-year OS: 91.0% 2,100 CT + lapatinib 1 year 4-year DFS: 82.0% 1.34 ( ; <0.0005) 2,091 CT + trastuzumab -> 6-year DFS: 84.0% lapatinib for 1 year 0.93 ( ; ns) 2,093 CT + trastuzumab + 6-year DFS: 85.0% lapatinib for 1 year 0.86 ( ; ns) 2405 CT + trastuzumab + placebo 3-year idfs:93.2% NR for 1 year 400 CT + trastuzumab + 3-year idfs: 94.1% NR pertuzumab for 1 year 0.81 ( ; ) NR 4-year OS: 93.0% 1.36 ( ; 0.007) 6-year OS: 92.0% 0.88 ( ; ns) 6-year OS: 93.0% 0.86 ( ; ns)
14 De-escalating HER2-directed Adjuvant Therapy Trial BCIRG 006 Slamon DJ, et al. SABCS, APT Tolaney SM, et al. N Engl J Med 2015; ASCO 2017, Abstr 511 Study Design No. of patients Treatment Arm DFS Absolute Values HR (95% CI; p) Non-anthracycline- based Cht OS Absolute Values HR (95% CI; p) Phase 3 1,073 AC -> T 10-year DFS: 67.9% 10-year OS: 78.7% Phase 3 (T1/2 N0) 1,074 AC -> TH -> Trastuzumab for 1 year 1,075 TCH -> Trastuzumab for 1 year 406 Weekly paclitaxel x 12 + trastuzumab for 1 year 10-year DFS: 74.6% 0.72 ( ; <0.0001) 10-year DFS: 73.0% 0.65 ( ; <0.0011) 7-year idfs: 93.3% 7-year OS: 95.0% 10-year OS: 85.9% 0.63 ( ; < year OS: 83.3% 0.76 ( ; <0.0075
15 De-escalating HER2-directed Adjuvant Therapy FinHER Trial Joensuu H, et al. J Clin Oncol PHARE Pivot X, et al. Lancet Oncol HORG Mavroudis D, et al. Ann Oncol Short-HER Conte PF, et al., ASCO 2017, Abstr 501. Study Design No. of patients Treatment Arm DFS Absolute Values HR (95% CI; p) Shorter duration of adjuvant Trastuzumab Phase Docetaxel or vinorelbine x 3 -> FEC x Docetaxel or vinorelbine x 3 -> FEC x 3 + trastuzumab for 9 weeks Phase 3 1,690 CT + trastuzumab for 1 year 1,690 CT + trastuzumab for 6 months Phase ddfec -> dddocetaxel + trastuzumab for 1 year 240 ddfec -> dddocetaxel + trastuzumab for 6 months Phase CT + trastuzumab for 1 year 626 CT + trastuzumab for 9 weeks OS Absolute Values HR (95% CI; p) 5-year distant DFS: 73.0% 5-year OS: 82.3% 5-year distant DFS: 83.3% 0.65 ( ; 0.12) 2-year DFS: 93.8% 2-year DFS: 91.1% 1.28 ( ; 0.29) 3-year DFS: 95.7% 3-year DFS: 93.3% 1.57 ( ; 0.137) 5-year DFS: 87.5.% 5-year DFS: 85.4% 1.15 ( ; ns) 5-year OS: 91.3% 0.55 ( ; 0,094) NR NR 1.46 ( ; 0.03) NR NR 1.45 ( ; NR NR
16 SHORT-HER: 9 weeks vs. 1 year Adjuvant Trastuzumab in Combination with Cht Conte PF, et al. ASCO 2017, Abstr 501.
17 Cardiac Safety of Adjuvant HER2-directed Agents Trial Arm Any CHF (%) Any LVEF drop (%) HERA, de Azambuja, et al. Chemo (2014) Chemo T 1y Chemo T 2y NSABP B-31, Romond, et al. AC P (2012) AC PT NCCTG N9831, Advani, et al. (2016) AC P AC P T AC PT BCIRG 006, Slamon, et al. AC D (2015) AC DT DCarboT APT, Tolaney, et al. (2015) PT ALLTO, Piccart M, et al. (2016) APHINITY, von Von Minckwitz, et al. (2017) Chemo T 1y Chemo T Lapa 1y Chemo T + Lapa 10y Chemo T 1y Chemo T + Pertu 1y < NR Risk factors for CHF: low LVEF, age, obesity, hypertension. LVEF is mandatory before initiation of trastuzumab and during treatment
18 Take Home Points 1 year of trastuzumab remains standard in adjuvant therapy of HER2-positive EBC! A dual HER2 blockade with pertuzumab or lapatinib or extended neratinib might be considered in higher risk HER2-positive patients (HR-negative, multiple-node positive), if available. ESMO MCBS pending! Trastuzumab plus paclitaxel seems to be appropriate therapy patients with T1 N0 disease. Shorter duration of trastuzumab may be considered in selected, low risk patients who can not tolerate 12 months of therapy. Additional biomarkers to identify HER2-positive patients suitable for escalation or de-escalation of adjuvant therapy are urgently needed!
19 HER2-directed Therapy of Advanced Breast Cancer (ABC)
20 Pivotal Trials of HER2-directed Therapy in Addition to Cht in HER2-positive MBC Trial Slamon, et al. 1 Smith, et al. 2 Marty, et al. 3 Di Leo, et al. 4 (ErbB2+ pts only) Guan, et al. 5 * statistically significant Treatment Trastuzumab + paclitaxel vs. paclitaxel Trastuzumab + docetaxel vs. docetaxel Lapatinib + paclitaxel vs. paclitaxel Lapatinib + paclitaxel vs. Paclitaxel ORR (%) 49 vs. 17* 61 vs. 34* 63 vs. 38* 69 vs. 50* TTP (months) 7.1 vs. 3.0* 11.7 vs. 6.1* 8.5 vs. 5.8* 9.7 vs. 6.5* OS (months) 25.1 vs. 18.0* 31.2 vs. 22.7* 24.0 vs. 19.8* 27.8 vs. 20.5* 1. Slamon, et al. N Engl J Med 2001.; 2. Smith, et al. Anticancer Drugs 2001.; 3. Marty, et al. J Clin Oncol 2005.; 4. Di Leo, et al. J Clin Oncol 2008.; 5. Guan, et al. J Clin Oncol 2013.
21 Pivotal trials on Add-on HER2-directed Therapy to Endocrine Therapy in HR+/HER2+ MBC Trial TAnDEM 1 EGF electra 3 Treatment arm Anastrozole +/- Trastuzumab Letrozole +/- Lapatinib Letrozole +/- Trastuzumab * Statistically significant difference. No. pts Median PFS / TTP (months) * * * Overall Response Rate (ORR) 7% 20%* 15% 28%* 13% 27%* Overall Survival (months) 1. Kaufman B, et al. J Clin Oncol 2009.; 2. Johnston S, et al. J Clin Oncol 2009.; 3. Huober J, et al. Breast NR
22 HER2-directed Therapy Beyond Progression Trial GBG-26 1 Treatment arm No. pts PFS Median (months) Median (months) HR (95% CI; p) OS HR (95% CI; p) Capecitabine Capecitabine + Trastuzumab ( ; 0.034) 0,76 ( ; 0.257) Capecitabine EGF Capecitabine ( ; <0.001) 0.78 ( ; NS) Lapatinib 1. Von Minckwitz G, et al ; 2. Cameron D, et al
23
24 Year 2017: HER2-directed Therapy for ABC All HER2+ Trastuzumab plus Taxanes Trastuzumab plus Vinorelbine (Eribulin, Capecitabine) Lapatinib plus Capecitabine Trastuzumab plus Pertuzumab plus Taxane T-DM1 Trastuzumab plus Lapatinib HER+ /HR+ Trastuzumab plus AI Lapatinib plus AI Tratuzumab plus Pertuzumab plus AI Trastuzumab plus Lapatinib plus AI
25 First-line HER2-directed Therapy of ABC: Pivotal trials HERNATA (type of Cht) Taxane + Trastuzumab vs. Vinorelbine + Trastuzumab No difference in PFS or OS (Andersson, et al. JCO 2011) MA.31 (type of HER2-directed agent) Taxane + Trastuzumab vs. Taxane + Lapatinib Trastuzumab plus Taxane sign. improvement in PFS, not in OS (Gelmon, et al. JCO 2015.) CLEOPATRA (dual HER2 blockade) Docetaxel + Trastuzumab vs. Docetaxel + Trastuzumab + Pertuzumab Trastuzuab plus Pertuzumab sign. improvement in PFS and OS (Swain, et al. NEJM 2015.) MARIANNE (dual HER2 blockade) Docetaxel/Pacltaxel + Trastuzumab vs. T-DM1 vs. T-DM1 + Pertuzumab T-DM1 or T-DM1 + Pertuzumab no sign. improvement in PFS, OS (Perez, JCO 2017.)
26 CLEOPATRA: First-line Trastuzumab and Docetaxel +/- Pertuzumab in HER2+ MBC Pertuzumab + trastuzumab+docetaxel Placebo + trastuzumab+docetaxel Hazard P-value ratio ORR % 69.3% PFS months 12.4 months 0.68 < OS months 40.8 months Long term cardiac safety maintained, with favorable LVEF and CHF in experimental arm! Swain S, et al. NEJM 2015.
27 HER2- directed plus ET in First-line Therapy of HR+/HER2+ ABC: Dual Blockade Trial PERTAIN** Arpino G et al., SABCS ALTERNATIVE Gradishar WJ et al., ASCO 2017, Abstr Treatment arm AI + Trastuzumab +/- Pertuzumab** AI + Trastuzumab AI + Lapatinib AI + Trastuzumab + Lapatinib No. pts Median PFS (months) * * * Statistically significant difference, ** Induction Cht with taxane allowed. Gradishar WJ, et al. ASCO 2017, Abstr Overall Response Rate (ORR) 56% 63% 14% 19% 32%* Dual HER2 blockade might be a reasonable option in HR+/HER2+ patients who are not candidates for Cht. Overall Survival (months) NR NR
28 Take Home Points: First-line HER2-directed Therapy ABC Trastuzumab plus pertuzumab and taxane represents the standard first-line therapy in ABC pts not receiving previous HER2-directed therapy. When pertuzumab is not given (available) trastuzumab plus taxane or vinorelbine should be given in first-line setting. One may consider T-DM1 as an effective and tolerable alternative to trastuzumab/taxane combination in the first-line setting, mainly for patients pre-treated with neo-/adjuvant HER2-directed therapy. For highly selected patients with HER2+/HR+ MBC for whom ET is chosen over or after Cht, concomitant ET plus HER2- directed therapy should be offered. Dual HER-2 blockade with trastuzumab plus pertuzumab or lapatinib may be considered.
29 Optimal Second-Line Therapy of ABC Prior Trastuzumab only EGF Lapatinib vs. Lapatinib +/- Trastuzumab Lapatinib + Trastuzumab sign. improvement in PFS and OS (Blackwell, et al. JCO 2012.) EMILIA T-DM1 vs. Capecitabine + Lapatinib T-DM1 sign. improvement in PFS and OS (Verna, et al. NEJM 2012.) PHEREXA Capecitabine + Trastuzumab +/- Pertuzumab Trastuzumab plus Pertuzumab no sign. difference in PFS (Urruticoechea, et al. ASCO 2016, Abstract 504.) Prior Trastuzumab and Lapatinib TH3RESA T-DM1 vs. Physician Treatment of Choice (PTC) T-DM1 sign. improvement in PFS and OS (Krop, et al. Lancet Oncol 2014.)
30 Proportion progression-free Proportion surviving EMILIA: T-DM1 vs. Lapatinib Plus Capecitabine in HER+ MBC Progression-Free Survival by Independent Review Time (months) No. at risk by independent review: Cap + Lap T-DM Unstratified HR=0.66 (P<0.0001). Verma S, et al. NEJM Median (months) No. of events Cap + Lap T-DM Stratified HR=0.650 (95% CI, 0.55, 0.77) P< T-DM Overall Survival: Confirmatory Analysis % 85.2% 51.8% 64.7% No. at risk: Time (months) Cap + Lap T-DM Data cut-off July 31, 2012; Unstratified HR=0.70 (P=0.0012). Lapatinib + capecitabine Median (months) No. of events Cap + Lap T-DM Stratified HR=0.682 (95% CI, 0.55, 0.85); P= Efficacy stopping boundary P= or HR=0.727 Hazard ratio P-value PFS 9.6 months 4.6 months 0.65 <0.001 OS 30.9 months 25.1 months 0.68 <
31 Take Home Points Patients progressing on HER2-directed therapy should continue it beyond progression. Optimal duration of HER2-directed therapy in ABC patients achieving CR is not yet known. Stopping HER-2 therapy might considered if re-challenge is available in case of progression. T-DM1 is considered the standard second-line treatment of HER2-positive ABC. Trastuzumab plus Cht, lapatinib plus capecitabine or trastuzumab plus lapatinib remain viable options in pre-treated patients. There are no data supporting dual HER2 blockade beyond progression. Patients with CNS disease benefit from HER2-directed therapy: trastuzumab, trastuzumab plus pertuzumab or T-DM1 are viable treatment options. Intrathecal trastuzumab might be considered in patients with leptomeningeal disease (Zagouri, et al. BCRT 2013).
Systemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationExiste-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More information(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC
(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC Rebecca Dent, MD FRCP (Canada) Senior Consultant, National Cancer Center Singapore Associate Professor, Duke-NUS www.abc-lisbon.org When to question a pathology report?
More information(Neo) Adjuvant systemic therapy for HER-2+ EBC
(Neo) Adjuvant systemic therapy for HER-2+ EBC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationTreatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationUpdate HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna
Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationCurrent and Future perspectives of HER2+ BC
2018.4.6 GBCC Satellite symposium Current and Future perspectives of HER2+ BC Jee Hyun Kim, M.D., Ph.D. Seoul National University Bundang Hospital Seoul National University College of Medicine Disclaimer
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationThe Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationTarget biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica
Target biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental
More informationTreatment of Early Stage HER2-positive Breast Cancer (One size does not fit all)
Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all) 8 November 2014 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More information2
1 2 Systematic review of published evidence PUBMED 1999-2017 ASCO 1999-2017 SABCS 1999-2017 ECCO/ESMO 1999-2017 3 Statement: Anthracycline/ taxane based chemotherapy 1. Budd GT et al. SWOG S0221: A Phase
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationShould pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
Commentary Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? Tom Wei-Wu Chen 1, Ching-Hung Lin 1,2, Chiun-Sheng Huang 3 1 Department of Oncology,
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More information(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer)
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Neoadjuvant
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationSYSTEMIC THERAPY FOR HER-2+ ABC
SYSTEMIC THERAPY FOR HER-2+ ABC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationTreatment of Early Stage HER2-positive Breast Cancer
Treatment of Early Stage HER2-positive Breast Cancer 3 November 2012 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky Lexington, KY Molecular Portrait
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationBREAST CANCER RISK REDUCTION (PREVENTION)
BREAST CANCER RISK REDUCTION (PREVENTION) Articles Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled
More informationDEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO
DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO
More informationAdjuvant Chemotherapy TNBC & HER2 Subtype
Adjuvant Chemotherapy TNBC & HER2 Subtype 2015.08.15 Gun Min Kim Yonsei Cancer Center Division of Medical Oncology Department of Internal Medicine Yonsei University College of Medicine gmkim77@yuhs.ac
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationDo we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD
Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar Paradigm shift? The Food and Drug Administration collaborative project P. Cortazar, Silver Spring, USA FDA Perspective: Moving from Adjuvant to Neoadjuvant Trials in
More informationNuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento
Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Prof. Sabino De Placido Dip. di Endocrinologia ed Oncologia
More informationBiomarker research in HER2 positive breast cancer : a journey into the desert
WIN 9th Symposium 2017 Expediting Global Innovation in Precision Cancer Medicine Paris, June 26 & 27, 2017 Biomarker research in HER2 positive breast cancer : a journey into the desert Martine J. Piccart-Gebhart,
More informationIl trattamento medico
III Sessione: La malattia in fase avanzata Il trattamento medico Emilio Bria Oncologia, Dipartimento di Medicina, Università di Verona, Azienda Ospedaliera Universitaria Integrata Verona emilio.bria@univr.it
More informationUpdates in HER2-Targeted Therapy from SABCS Outline
Updates in HER2-Targeted Therapy from SABCS 2018 Melanie Majure, MD Assistant Professor University of California San Francisco Helen Diller Comprehensive Cancer Center Outline Neoadjuvant Therapy (PEONY;
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationSessione 4: La malattia metastatica. La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G.
Sessione 4: La malattia metastatica La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo giusyricciardi81@hotmail.it
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Management of HER2+ MBC SOBO 2012 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for Women s Cancer
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationEARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
More informationTreatment of HER2+ and Triple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA
Treatment of HER2+ and Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA ewiner@partners.org Disclosure Disclosure Consultant Tessaro, Leap, Genentech Off Label/Investigational
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationNeoadjuvant and Adjuvant Therapy for HER2 Positive Disease
ADJUVANT AND NEOADJUVANT THERAPY FOR HER2-POSITIVE DISEASE Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease Stephen K. Chia, MD, FRCP(C) OVERVIEW Since the initial description of the HER2 proto-oncogene
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationHighlights. Padova,
Highlights P Pronzato Padova, 17.11.2012 Last 12 Months Main Meetings SABCS 2011 (San Antonio) EBCC 8 2012 (Wien) ASCO 2012 (Chicago) ESMO/ECCO 2012 (Wien) The Medical Oncology Job Risk Manager Strategy
More informationAdjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationNon-anthracycline Adjuvant regimens in Early Breast Cancer. Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center
Non-anthracycline Adjuvant regimens in Early Breast Cancer Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center Contents Role of Anthracyclines in adjuvant treatment EBCTCG2012
More informationHER2 Positive Breast Cancer
HER2 Positive Breast Cancer Charles E. Geyer, Jr. MD, FACP Professor of Medicine Division of Hematology, Oncology and Palliative Care Virginia Commonwealth University Associate Director of Clinical Research
More informationWhat is the Next Goal for HER2 Targeted Therapy?
What is the Next Goal for HER2 Targeted Therapy? Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education University of California San Francisco Helen Diller Family Comprehensive Cancer
More informationPRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationKazuhiro Araki, Yasuo Miyoshi
Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo
More informationSystemic therapy for HER2+ Advanced Breast Cancer
Systemic therapy for HER2+ Advanced Breast Cancer F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationJ Clin Oncol 32: by American Society of Clinical Oncology INTRODUCTION
VOLUME 32 NUMBER 19 JULY 1 2014 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra
More informationTreatment of HER2+ and Triple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA
Treatment of HER2+ and Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA ewiner@partners.org Disclosure I have nothing to disclose. Off Label/Investigational Discussion
More informationAdvances in the Management of Metastatic Her 2 Positive Breast Cancer
Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook
More informationBreast Cancer: Chemotherapy and Novel Agents
North Carolina Oncology Association & South Carolina Oncology Society Joint Membership Meeting ~ February 26 27, 2010 The Ballantyne Resort ~ Charlotte, NC Breast Cancer: Chemotherapy and Novel Agents
More information(Neo-) Adjuvant chemotherapy and biological agents. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
(Neo-) Adjuvant chemotherapy and biological agents Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Neoadjuvant treatment in triple negative and HER2 positive
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationUpdate on HER2-Positive Adjuvant Therapy
UPDTE ON HER2-POSITIVE DJUVNT THERPY Update on HER2-Positive djuvant Therapy Reshma Mahtani, DO; na Sandoval, MD; and Mohammad Jahanzeb, MD bstract HER2-positive breast cancer accounts for 15% to 2% of
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationSANDRA M. SWAIN. Washington Cancer Institute, Washington, District of Columbia, USA
The Oncologist Early-Stage Breast Cancer: Clinical Update Chemotherapy: Updates and New Perspectives SANDRA M. SWAIN Washington Cancer Institute, Washington, District of Columbia, USA Key Words. Breast
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationBREAST CANCER SLIDE DECK 2017 Selected abstracts from:
BREAST CANCER SLIDE DECK 2017 Selected abstracts from: 2017 ASCO ANNUAL MEETING 2 6 June 2017 Chicago, USA Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the content of this
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationSANDRA M. SWAIN. Washington Cancer Institute, Washington, District of Columbia, USA
The Oncologist Chemotherapy: Updates and New Perspectives SANDRA M. SWAIN Washington Cancer Institute, Washington, District of Columbia, USA Key Words. Breast cancer Chemotherapy Taxane Trastuzumab Ki-67
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationTITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
TITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Table of Contents Data Supplement 1: Additional Evidence
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More information